In this study, we further suggest that osimertinib induces proteasomal degradation of Topo IIα, likely via a GSK3-dependent and FBXW7-mediated mechanism, in EGFRm NSCLC cells, since inhibition of either GSK3 or FBXW7 rescued Topo IIα reduction induced by osimertinib. This evidence concerns the gene FBXW7 and non-small cell lung carcinoma.